99% correct,, well over half way ,, had there been a Safety or Tolerability issue it would be all over in week 1.
The Trial is still only Registered as a Phase I on the ANZCTR.. you cant dredge a trial for Data , only the data sought can be used moving forward..
Now the dose has been increased and still no intervention by the Safety Regulator bodes extremely well.... NZT
Many dont make it this far,, this is a 1st in class medicine with a Brand New Micronised MPL Tablet that has been approved for trialing in Humans.. the is truly significant ,,also regrettably MND is terminal and all of the Trial Patients have elected to stay on the Trial....again hugely significant..
But as the Company has progressed the Value has diminished,, IMHO if the Market was better informed we may not have seen the near 50% decline in a month..NZT Other Bio's are building excitement and expectations surrounding their results ..PAA? well the SP demonstrates Managements ability to impart value.......Poor
PAA Price at posting:
6.6¢ Sentiment: Buy Disclosure: Held
(20min delay)